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Background: Treatment of primary renal cell carcinoma using radiotherapy with curative intent is rare, because
renal cell carcinoma is generally regarded as a radiation-resistant tumor. Recently, stereotactic body radiation
therapy has been radically applied for cancers in various organs including renal cell carcinoma. However, there were
few reports describing pathological changes of renal cell carcinoma post stereotactic body radiation therapy. This is
the first report we are aware of documenting late histological effects of stereotactic body radiation therapy on renal
cell carcinoma and surrounding normal tissue.
Case presentation: A right renal tumor was identified in a Japanese 70-year-old man on follow-up computed
tomography for his chronic hepatitis. T1N0M0 renal cell carcinoma was clinically diagnosed as the tumor was 3 cm
in diameter and well-enhanced with intravenously infused contrast material in the arterial phase on computed
tomography. No metastases in regional lymph nodes or distant sites were evident. Stereotactic body radiation
therapy was selected as an alternative therapy to surgery because of his poor liver function. A total dose of 60 Gy
in 10 fractions over 12 days was delivered using a 10-megavolt X-ray. The renal tumor gradually decreased in size
and partial response had been achieved at 2 years after completing stereotactic body radiation therapy. Hepatocellular
carcinoma was identified during follow-up in the patient and he died of progression of hepatocellular carcinoma with
hepatic failure 2.5 years after completing stereotactic body radiation therapy. Autopsy was done and it showed almost
complete necrosis of tumor tissues with a small amount of viable renal carcinoma cells. These pathological findings
suggested marked effects of stereotactic body radiation therapy on clear cell renal cell carcinoma.
Conclusion: Our case demonstrates a good pathological response with small foci of remnant viable cancer cells after
stereotactic body radiation therapy of 60Gy in 10 fractions for small renal cell carcinoma. Although further experiences
and longer follow-up are mandatory to conclude the optimal treatment schedule and efficacy of stereotactic body
radiation therapy for renal cell carcinoma, stereotactic body radiation therapy may represent a novel less-invasive
option for the treatment of primary renal cell carcinoma.
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Figure 1 Initial CT, radiotherapy planning, and follow-up CT.
(A) Axial contrast-enhanced computed tomography image before
stereotactic body radiation therapy. (B) Dose distribution of the
planning for stereotactic body radiation therapy. Isodose lines
show 70Gy, 60Gy, 50Gy, 40Gy, 30Gy, 20Gy, and 10Gy from the
inside. (C) Axial contrast-enhanced computed tomography image
two years after SBRT. The renal tumor decreased in size and its
surrounding renal portion got atrophic.
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In the recent era of rapidly aging populations, minimally
invasive treatment modalities are preferred for elderly
patients with various cancers, including renal cell carcin-
oma (RCC). RCC accounts for approximately 2% of all
new cancer incidences worldwide, and has traditionally
thought to be a radio-resistant malignancy [1,2]. Radio-
therapy (RT) has thus played little role in the manage-
ment of primary RCC, and few reports have described
curative radiotherapy for primary RCC. Conventional ra-
diation to a total of 60 Gy or so in 1.8- to 2-Gy daily
fractions has not proven very effective in controlling the
tumor in curative or adjuvant settings. The role of con-
ventional RT is mainly palliative for metastatic disease,
producing a subjective or objective response in about
50% of symptomatic patients [2]. Brain metastases from
RCC have recently been successfully treated with ste-
reotactic radiosurgery (SRS), providing local control
rates exceeding 85% [3,4]. Advances in technology and
methods in radiation oncology have led to the clinical
implementation of image-guided RT (IGRT) and body
stereotaxis, allowing the delivery of very high, biologic-
ally potent doses to extracranial tumors. Primary RCC
and its metastases to extra-cranial sites may thus now be
treated with similar success using stereotactic body radi-
ation therapy (SBRT) [5,6]. SBRT has been available for
more than 10 years and is gaining clinical interest as a
means of achieving local radical treatment of tumors in
various organs, particularly for patients with stage I non-
small-cell lung cancer (NSCLC) [7,8], however, histo-
logical late effects of SBRT for primary RCC have not
previously been shown. We report herein the case of a
patient who underwent treatment of primary RCC
treated with SBRT and autopsy after his death. This is
the first reported case to demonstrate late histological
effects on primary RCC and surrounding normal tissue
after SBRT.
Case presentation
On follow-up computed tomography (CT) for chronic
hepatitis, a right renal tumor was identified in a Japanese
70-year-old man. The renal tumor was 3 cm in diameter
and located in the posterolateral portion of the right kid-
ney (Figure 1A). The lesion showed good enhancement
with intravenously infused contrast material in the arter-
ial phase on CT and was considered to be RCC clinically.
No metastases in regional lymph nodes or distant sites
were evident on whole-body CT, therefore T1N0M0
RCC was diagnosed. The patient was judged as high-risk
for surgery due to his poor liver function. He expressed
a desire to undergo SBRT as local intensive therapy though
we explained to him that SBRT was a new, non-standard
treatment for renal cell cancer. To minimize respiratory
motion of the kidney during irradiation, the patient wastrained in voluntary self-breath-holding during the inspir-
ation phase using a respiratory indicator. Planning target
volume (PTV) was determined as the gross tumor volume
of the right renal mass plus the personal internal margin
with an additional margin of 3 mm to compensate for
intra-session reproducibility and to provide a safety mar-
gin. Tumor position was adjusted to the planned position
Figure 2 Macroscopic findings of clear cell renal cell carcinoma
treated with stereotactic radiotherapy. On the cut surface of the
autopsied kidney tissue, a 2.4 × 1.6 cm tumor mass with clear
margins, blackish-brown in color, is recognizable in the atrophic
kidney tissue.
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of the tumor. Ten different non-coplanar static beams
were used for irradiation. The radiation port was made
with sliding multileaves adjusted with 3-mm margins
around the border of the PTV. A total dose to the center
of 60 Gy in 10 fractions over 12 days was delivered using a
10-MV X-ray. Targets delineations and isovalue lines writ-
ten on CT are shown in Figure 1. Ninety-five percent of
the PTV was within the 95% isodose line to the prescribed
dose (Figure 1B). No clinical acute or chronic side effects
were recorded during or after treatment, which was well
tolerated. The renal tumor slowly but continuously de-
creased in size and partial response had been achieved at
2 years after completing SBRT, and its surrounding renal
portion got atrophic (Figure 1C). Hepatocellular carcin-
oma was identified during follow-up and the patient died
of progression of this malignancy and liver dysfunction
2.5 years after completing SBRT. Autopsy was performed
and the right renal tumor treated with SBRT was patho-
logically examined.
On autopsy, a well-circumscribed, blackish-brown solid
tumor, measuring 2.4 × 2.0 × 1.6 cm, was evident on the
cut surface of the lower portion of the right kidney speci-
men accompanying atrophic change (Figure 2). Histologi-
cally, this tumor was surrounded by a distinct fibrous
capsule and almost the entire tumor showed hemorrhagic
necrosis (Figure 3A), although a small number of degen-
erative carcinoma cells with abundant, clear and/or ves-
icular cytoplasm and nuclei with mild to moderate
pleomorphism remained (Figure 3B). Focal fibrosis,
edema and aggregated foamy macrophages were also
observed (Figure 3C). These pathological findings sug-
gested marked effects of SBRT on clear cell RCC.
Discussion
Conventional radiotherapy is not considered to have a
role to play in the definitive management of RCC. SBRT
offers the only non-invasive, highly efficient means of
eradicating small-sized tumors at primary or metastatic
sites. Effects of hypofractionated single high-dose irradi-
ation on RCC have been demonstrated in several papers.
In an animal study, Walsh et al. irradiated a nude mice
xenograft model injected subcutaneously with A498 hu-
man renal carcinoma cells with three fractions (one per
week) for a total dose of 48 Gy [9]. All irradiated tumors
subsequently decreased gradually in size and exhibited
marked cytological changes. In a human study, Svedman
et al. reported a good local control rate of 98% on im-
aging after SBRT noted in a prospective study involving
30 patients with metastatic or inoperable primary RCC
[6]. Gerszten et al. showed that two patients with medic-
ally inoperable primary RCC also did well with pain relief
and stable disease on imaging [10]. Beitler et al. described
a series of nine patients with primary RCC treated withSBRT, noting four long-term survivors (minimum follow-
up, 48 months) [11]. Teh et al. concluded that image-
guided SBRT provides excellent local control on imaging
without any significant toxicity, and SBRT may represent
a novel, non-invasive, nephron-sparing option for the
treatment of primary RCC [12]. Histologically, Ponsky
et al. reported three cases of pathological evaluation of
RCC at eight weeks after SBRT [13]. In the report, histo-
logical complete response was found in one of three pa-
tients with primary RCC after receiving SBRT dose of
16 Gy in 4 fractions. To our knowledge, it is the only re-
port describing histological change of primary RCC
after SBRT, however the duration between SBRT and
histological examination was very short (eight weeks).
Figure 3 Histological findings of clear cell renal cell carcinoma
treated with stereotactic radiotherapy. (A) The tumor at low
magnification shows markedly hemorrhagic findings within a fibrous
capsule. (B) A high-power view demonstrating clustered,
degenerative cancer cells with abundant, clear and/or vacuolated
cytoplasm and round-to-ovoid or irregularly-shaped nuclei with a
hemorrhagic background. (C) Aggregation of foamy macrophages in
the fibrotic stroma.
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tissues would be expected to change after eight weeks.
In addition, the dose of SBRT in Ponsky’s report is muchlower than that of ours. Therefore we believe the current
case report has a novel finding that demonstrated late
histological effects at 2.5 years after high dose SBRT on
primary RCC.
Essentially no significant treatment-related toxicity was
noted in patients with metastatic RCC and primary RCC
treated with SBRT in above reported series, including the
present case. This is likely due to the precise delivery of
high-dose radiation and the use of stereotactic and IGRT
technology. Because of the rapid falloff in isodose lines,
only very limited normal tissues beyond the tumor target
received high-dose radiation. No severe deterioration of
renal function as well as functions of other normal organs
was seen in patients whose primary RCC received SBRT.
SBRT may also play an important role especially in pa-
tients with recurrent RCC in the remaining kidney, for
which the preservation of renal function is of utmost im-
portance. In contrast to other local therapeutic modalities
such as radio-frequency ablation, surgery and cryotherapy,
radiotherapy is the least invasive therapeutic procedure
for patients.
Determining the optimal SBRT fractionation schedule is
difficult, because of heterogeneity in the doses used and
because the true α/β of RCC is not clear. Ning et al. deter-
mined α/β values for RCC cell lines A498 and Caki-1 as
2.6 and 6.92, respectively [14]. If the α/β of RCC is very
small, the large fraction size of SBRT may be advanta-
geous to decrease chronic adverse effects on surrounding
normal tissue while maintaining a biological effect for
tumor control. More work is required to determine the
most appropriate α/β values and optimal dose for RCC,
especially using the SBRT approach. On the other hand, if
hypoxia is one of the important factors determining
“radioresistance” in RCC, longer fractionation schedules
with moderately high-dose fractions beyond 5–6 fractions
may be better than 1–3 fractions with ultra-high dose. Ac-
cording to the local histopathological effects seen in this
case, slightly greater tumoricidal efficacy might be neces-
sary. Despite all the above-mentioned shortcomings, the
present case showed encouraging pathological effects, but
small foci of remnant viable cancer cells after SBRT. Car-
bon ion radiation therapy may be valuable in order to
achieve more strong radiobiological effect and keep nor-
mal organs around the kidney away from radiation toxicity
[15], but it needs extremely large cost and space.
Although further experience and longer follow-up are
mandatory to confirm the optimal treatment schedule
and efficacy of SBRT for RCC, SBRT may represent a
novel non-invasive, nephron-sparing option for the treat-
ment of primary RCC.
Conclusion
The present case showed a good pathological response
with small foci of remnant viable cancer cells after SBRT
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experiences and longer follow-up are mandatory to con-
clude the optimal treatment schedule and efficacy of
SBRT for RCC, SBRT may represent a novel non-invasive,
nephron-sparing option for the treatment of primary
RCC.
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